ECaBox (964342)

  https://cordis.europa.eu/project/id/964342

  Horizon 2020 (2014-2020)

  "ECaBox ""Eyes in a Care Box"": Regenerating human retina from resuscitated cadaveric eyes"

  FET-Open Challenging Current Thinking (FETOPEN-01-2018-2019-2020)

  ophthalmology  ·  physiology  ·  transplantation

  2021-09-01 Start Date (YY-MM-DD)

  2025-08-31 End Date (YY-MM-DD)

  € 3,552,143 Total Cost


  Description

In the last decade, basic and translational research dramatically expanded the development of new drug and regenerative therapies. Nevertheless, numerous potential therapies end up in the “valley of death” due to high attrition rates of preclinical development. More cost-effective preclinical research is needed to support radically new therapeutic interventions (e.g. regenerative medicine). Yet, preclinical research still lacks adequate models of human organs and even though human organoids approaches are a major step forward in mimicking physiological conditions, they fail to reflect the overall tissue physiology and complexity. To address this demand, we aim to develop a revolutionary platform, the ECaBox (Eyes in a Care Box) to resuscitate the human cadaveric eye while ensuring eye function and structure ex vivo for an unmatched time-period. This new technology will challenge current paradigms of testing the efficacy and safety of regenerative therapies ex vivo. We will therefore, explore the potential of this forefront technology by testing a regenerative therapy approach for retina degeneration. Currently, human eyes can be kept at 4ºC for 2 days before going massive and irreversible cell and tissue damage. Human dissected retinae from cadaveric eyes can be preserved for maximum 1 week and non-vascularised human eye organoids fail to recapitulate the vascular and tissue systems. Hence, ECaBox will be a disruptive technology with a tremendous impact allowing to: 1) resuscitate human eyes to test human eye therapies ex vivo, 2) bypass major ethical restrictions of human experimentation, 3) serve as a proof of concept to develop therapies also in other organs preserved ex vivo and 4) transform the existing organ transplantation field. This is a highly interdisciplinary project that integrates expertise in biology, biotechnology, modelling, engineering and physics.


  Complicit Organisations

1 Israeli organisation participates in ECaBox.

Country Organisation (ID) VAT Number Role Activity Type Total Cost EC Contribution Net EC Contribution
Portugal ASSOCIATION FOR THE ADVANCEMENT OF TISSUE ENGINEERING AND CELL BASED TECHNOLOGIES & THERAPIES (953089700) PT508291402 participant REC € 538,648 € 538,648 € 538,648
Spain FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA (999528450) ESG64045719 participant REC € 232,960 € 232,960 € 232,960
Italy AFERETICA SRL (937953820) IT03330561204 participant PRC € 382,082 € 382,082 € 382,082
Israel BAR ILAN UNIVERSITY (999886574) IL580063683 participant HES € 355,125 € 355,125 € 355,125
Spain UNIVERSITAT DE BARCELONA (999986387) ESQ0818001J participant HES € 301,667 € 301,667 € 301,667
Spain FUNDACIO CENTRE DE REGULACIO GENOMICA (999544455) ESG62426937 coordinator REC € 1,299,376 € 1,299,376 € 1,299,376
United Kingdom KING'S COLLEGE LONDON (999981052) GB627403551 participant HES € 442,283 € 442,283 € 442,283